Just Released: New Research on Calithera, Akers, S&W Seed, Hovnanian, and Belden
NEW YORK, December 11, 2014 /PRNewswire/ --
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations. Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only. To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
CALA Research Report: (http://get.realtimeequities.com/pdf/?c=Calithera%20Biosciences&d=11-Dec-2014&s=CALA),
AKER Research Report: (http://get.realtimeequities.com/pdf/?c=Akers%20Biosciences&d=11-Dec-2014&s=AKER),
SANW Research Report: (http://get.realtimeequities.com/pdf/?c=S%26W%20Seed&d=11-Dec-2014&s=SANW),
HOV Research Report: (http://get.realtimeequities.com/pdf/?c=Hovnanian%20Enterprises&d=11-Dec-2014&s=HOV),
BDC Research Report: (http://get.realtimeequities.com/pdf/?c=Belden&d=11-Dec-2014&s=BDC).
Analyst Update: Strategic Agreements,Purchase Orders,Patent Filing, Earnings, and Acquisitions
Reviewed by: Rohit Tuli, CFA®
The US stock market on December 10, 2014 ended the day in red, led by a sharp decline in oil stocks amid the investor concerns about the global-economic slowdown. The Dow Jones industrial average fell 1.51%, the S&P 500 edged 1.64% lower, and the NASDAQ Composite declined 1.73%. The Oil price on Wednesday fell 4.5% to $60.94 a barrel, down 43% from this year's high after Organization of the Petroleum Exporting Countries (OPEC) reduced its forecasts for crude oil production in 2015 owing to the swelling supply from North America and other rising producers. The Asian stock markets ended the day on a mixed note with fresh concerns over slumping oil price and Greece's weak economy, which was offset by a strong rebound in Shanghai Composite Index. The European stocks renounced gains with the turnaround led by a slump in energy shares as oil prices extended their losses.
Calithera Biosciences Inc (Calithera) has gained exclusive, worldwide rights to research, develop and commercialize Mars Symbioscience's (Symbioscience's) portfolio of arginase inhibitors for use in human healthcare. The agreement is expected to boost Calithera's efforts to submit an Investigational New Drug application for an arginase inhibitor with the FDA for the treatment of cancer near the end of 2015. Click on the report below to find out rationale behind this deal as well as its financial terms.
Akers Biosciences Inc. (Akers) has bagged an initial purchase order worth $1 million from Beijing-based NovoTek Therapeutics Inc. ("NovoTek") to supply PIFA Heparin PF4/Rapid Assay products in China. Akers' tests will be first approved diagnostic assay in China to assist in the diagnosis of the allergy to the widely used blood-thinner, heparin. Click on the report below to know more about potential for Akers' tests in China.
S&W Seed Company (S&W Seed) has filed a patent application with the U.S. Patent and Trademark Office for stevia plant variety "SW201" which exhibits an improved leaf taste profile and considered as fit for producing fresh and dry leaf stevia. SW201 is believed to be the world's first stevia variety that was specifically bred for consumption as fresh and dried leaf. Click on the report below to find out more about these patent filings.
Hovnanian Enterprises, Inc. (Hovnanian) has posted a growth in revenues and earnings for the fourth quarter fiscal 2014 despite continued slowdown in the housing industry. Net income of the Company came in at $322.5 million, or $1.95 per diluted share, compared with $32.8 million, or $0.21 per diluted share in Q4 FY 2013. Click on the report below to find out what led Hovnanian's profit growth and other key financials of the Company.
Network infrastructure solutions provider Belden Inc. (Belden) has agreed to acquire Portland-based cybersecurity firm Tripwire for $710 million in cash. Belden said that the transaction is expected to add $0.65 per diluted share to adjusted income from continuing operations in 2015. Click on the report below to know how this acquisition will extend Belden's capabilities.
About Realtime Equities
Tired of missing trades? In a world where information travels at the speed of light, you can't afford to be out of touch. Get an actionable source of information. Find the best opportunities available in real-time. Don't waste time trying to chase the news, get ahead of it with Realtime Equities. We find information as it happens and send it out to our subscribers in our e-alerts. Our focus is to find companies positioned to see upward momentum, delivering alerts to your inbox as the event unfolds in realtime. Join us in our battle to beat the markets, you'll be happy you did.
We are proud to serve professional traders, financial advisors, hedge funds and experience individual investors including some of the top firms on wall-street today. For more information about our service offerings and subscriptions, please visit our website or reach out to our sales staff. Advanced subscription packages are available to qualifying institutional clients and accredited investors, please speak with your account manager to learn more about these custom opportunities.
If you enjoyed today's content, subsribe to our live updates here: ( http://get.realtimeequities.com/updates )
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Realtime Equities, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Realtime Equities in this article or report according to the procedures outlined by Realtime Equities. Realtime Equities is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.realtimeequities.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Realtime Equities
Share this article